Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres Forero

Showing results (71-80 of 179) with videos related to

Pageof 18
Sort By:
Molecular Cancer Therapeutics|March 30, 2018
Trastuzumab-Resistant HER2<sup>+</sup> Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) InhibitionMonica E Wielgos, Zhuo Zhang, Rajani Rajbhandari, et al.
British Journal of Haematology|September 6, 2018
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphomaDavid J Andorsky, Kathryn S Kolibaba, Sarit Assouline, et al.
Breast Cancer Research and Treatment|February 3, 2023
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancerChristos Vaklavas, Erica M Stringer-Reasor, Ahmed M Elkhanany, et al.
Blood|September 18, 2015
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and olderAndres Forero-Torres, Beata Holkova, Jerome Goldschmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Cancer Research|October 17, 2008
Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imagingHyunki Kim, Desiree E Morgan, Donald J Buchsbaum, et al.
Nature Reviews. Clinical Oncology|December 30, 2016
The landscape of new drugs in lymphomaAnas Younes, Stephen Ansell, Nathan Fowler, et al.
Leukemia & Lymphoma|December 24, 2013
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacyAjay K Gopal, Nancy L Bartlett, Andres Forero-Torres, et al.
Oncotarget|May 13, 2017
Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growthTaylor B Turner, Selene Meza-Perez, Angelina Londoño, et al.
Annals of Surgical Oncology|July 26, 2014
Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017Kandace P McGuire, E Shelley Hwang, Alan Cantor, et al.
Pageof 18

Showing results (71-80 of 179) with videos related to

Sort By:
Pageof 18
Molecular Cancer Therapeutics|March 30, 2018
Trastuzumab-Resistant HER2<sup>+</sup> Breast Cancer Cells Retain Sensitivity to Poly (ADP-Ribose) Polymerase (PARP) InhibitionMonica E Wielgos, Zhuo Zhang, Rajani Rajbhandari, et al.
British Journal of Haematology|September 6, 2018
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphomaDavid J Andorsky, Kathryn S Kolibaba, Sarit Assouline, et al.
Breast Cancer Research and Treatment|February 3, 2023
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancerChristos Vaklavas, Erica M Stringer-Reasor, Ahmed M Elkhanany, et al.
Blood|September 18, 2015
Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and olderAndres Forero-Torres, Beata Holkova, Jerome Goldschmidt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 20, 2014
Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I studyMichelle A Fanale, Steven M Horwitz, Andres Forero-Torres, et al.
Cancer Research|October 17, 2008
Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imagingHyunki Kim, Desiree E Morgan, Donald J Buchsbaum, et al.
Nature Reviews. Clinical Oncology|December 30, 2016
The landscape of new drugs in lymphomaAnas Younes, Stephen Ansell, Nathan Fowler, et al.
Leukemia & Lymphoma|December 24, 2013
Brentuximab vedotin in patients aged 60 years or older with relapsed or refractory CD30-positive lymphomas: a retrospective evaluation of safety and efficacyAjay K Gopal, Nancy L Bartlett, Andres Forero-Torres, et al.
Oncotarget|May 13, 2017
Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growthTaylor B Turner, Selene Meza-Perez, Angelina Londoño, et al.
Annals of Surgical Oncology|July 26, 2014
Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017Kandace P McGuire, E Shelley Hwang, Alan Cantor, et al.
Pageof 18